initial public offerings (IPOs) trading on American exchanges

Wednesday, August 12, 2015

Global Blood Therapeutics (GBT) began trading on the Nasdaq on 12 Aug 2015

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
  • Sector: Healthcare
  • Industry: Biotechnology
  • Founded in 2011 
  • Headquartered in South San Francisco, California

No comments:

Post a Comment